E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.

CONCLUSION: Motesanib (AMG 706) demonstrated a 4-month PFS that met the per-protocol definition of efficacy. Fatigue and hypertension were the most common toxicities, and few grade 3-4 toxicities were encountered. The progression-free survival of 8.7 months in all NETs merits further study. The Oncologist 2018.
PMID: 29853660 [PubMed - as supplied by publisher]

Source: The Oncologist - May 31, 2018 Category: Cancer & Oncology Authors: Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Louis Hinshaw J, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A Tags: Oncologist Source Type: research